Strategic National Stockpile

SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®

Retrieved on: 
Thursday, July 27, 2023
Biomedical Advanced Research and Development Authority, Strategic National Stockpile, IV, Office of Inspector General, U.S. Department of Health and Human Services, Human services, U.S. Department of Defense Strategy for Operating in Cyberspace, Administration for Strategic Preparedness and Response, TPOXX, Administration, Development, SIGA Technologies, Shipbuilding contract, BARDA, Vaccine

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services exercised procurement options for the delivery of approximately $113 million worth of oral TPOXX® treatment courses and approximately $25 million worth of IV TPOXX® treatment courses.

Key Points: 
  • NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services exercised procurement options for the delivery of approximately $113 million worth of oral TPOXX® treatment courses and approximately $25 million worth of IV TPOXX® treatment courses.
  • “Building on the orders SIGA received for TPOXX from 13 international customers and the U.S. Department of Defense in 2022, these most recent procurement orders further highlight that many global leaders in public heath recognize the importance of orthopoxvirus preparedness and the need to take action to keep people safe,” said Phil Gomez, CEO of SIGA.
  • “We are pleased that we are able to consistently meet demand for oral TPOXX, which is driving substantial and increasingly diversified global revenue opportunities at SIGA.”
    SIGA expects to fully deliver approximately $113 million of oral TPOXX under this order in 2023 and expects to start delivering IV TPOXX under this order in 2024.
  • Prior to delivery of IV TPOXX under this order, SIGA will be focused on fulfilling delivery obligations under a prior IV TPOXX order.

Emergent BioSolutions Announces CEO Transition

Retrieved on: 
Tuesday, June 27, 2023
Travel, ACAM2000, Strategic National Stockpile, EBS, Public, Culture, COVID-19, Smallpox, Infection, Sale, Government, Patient, Growth, Anthrax, NYSE, Berkeley Research Group, Emergent

GAITHERSBURG, Md., June 27, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS, “Emergent” or the “Company”) today announced that Robert G. Kramer Sr. has informed the Board of Directors of his intention to retire from Emergent. Mr. Kramer will step down from his role as President and CEO of Emergent and as a member of the Company’s Board, effective immediately. The Board has appointed Haywood Miller as interim CEO while it conducts a search to identify a new permanent CEO, considering both internal and external candidates and with the assistance of a leading executive search firm. Mr. Miller, Managing Director at Berkeley Research Group (“BRG”), has served as an advisor to the Company and its executive management team for the last several months. In order to ensure a smooth transition, Mr. Kramer will serve as an advisor to the Company until August 1, 2023.

Key Points: 
  • GAITHERSBURG, Md., June 27, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS, “Emergent” or the “Company”) today announced that Robert G. Kramer Sr. has informed the Board of Directors of his intention to retire from Emergent.
  • Mr. Kramer will step down from his role as President and CEO of Emergent and as a member of the Company’s Board, effective immediately.
  • The Board has appointed Haywood Miller as interim CEO while it conducts a search to identify a new permanent CEO, considering both internal and external candidates and with the assistance of a leading executive search firm.
  • In order to ensure a smooth transition, Mr. Kramer will serve as an advisor to the Company until August 1, 2023.

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

Retrieved on: 
Monday, February 27, 2023
USG, Anthrax, Acquisition, MCM, Investment, Strategic National Stockpile, AstraZeneca, SNS, Vaccine, Video game, Smallpox, Adjuvant, Janssen, Vaccinia

For Q4 2022, revenues from ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) decreased $125.8 million to $0.0 as compared with Q4 2021.

Key Points: 
  • For Q4 2022, revenues from ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) decreased $125.8 million to $0.0 as compared with Q4 2021.
  • For Q4 2022, revenues from nasal naloxone products decreased $29.5 million as compared with Q4 2021.
  • TEMBEXA® (brincidofovir) sales, following the Company’s September 2022 acquisition of worldwide rights to TEMBEXA®, contributed $117.6 million in revenues for Q4 2022.
  • For Q4 2022, revenues from contract development and manufacturing services decreased $33.5 million as compared with Q4 2021.

RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published

Retrieved on: 
Monday, November 14, 2022
Cell, Awareness, Thallium, Literature, Acceleration, Half-life, Caesium, Americium, Infection, TBI, International Journal of Molecular Sciences, La Trobe Institute for Molecular Science, Face, Strategic National Stockpile, Radiation, Survival, Government, Radiation exposure, B cell, Iodine, FDA, Filgrastim, Apsis, TEL, Chemoradiotherapy, Head, Mouse, Acute radiation syndrome, TNF, Total body irradiation, Safety, Extrapyramidal system, Nutrient, Toxicity, Inflammation, Homeland, Redhill, Chronic radiation syndrome, Opaganib, Plutonium, Animal, DTPA, Stem cell, Company, Nasdaq, Potassium iodide, Canadian International Council, Disease, Radiation damage, COVID-19, Bone marrow, Curium, MCM, Medical imaging, Pharmaceutical industry, Food preservation, Prussian blue (disambiguation)

The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.

Key Points: 
  • The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.
  • Much of the damage caused by radiation exposure is caused by inflammation secondary to the effects of ionizing radiation itself known as Acute Radiation Syndrome.
  • Again, opaganib was not associated with a diminished tumor response to fractionated radiation treatment and increased weight loss from radiation treatment was not observed.
  • Data from the opaganib global Phase 2/3 study has been submitted for peer review and recently published in medRxiv .

Humanetics Corporation Presents at the 68th Annual International Radiation Research Society Meeting

Retrieved on: 
Tuesday, October 25, 2022
Oncology, Defense, Health, Clinical Trials, Pharmaceutical, Other Defense, Biotechnology, Department of the Army Civilian Police, Development, Humanetics, Degenerative disease, Strategic National Stockpile, Policy, Patient, Data, Privacy and the US government, Radiation damage, Trial of the century, Doctor of Philosophy, Military personnel, Department, Department of Defence, Pharmacokinetics, Safety, Injection, Radiation, Inflammation, Government, Federal government of the United States, FDA, COVID-19, BIO, Army, Biomarker, Pharmaceutical industry, Research

Humanetics Corporation (Humanetics) presented data related to its new drug candidate, BIO 300, at the 68th Annual International Radiation Research Society Meeting, October 16-19, 2022.

Key Points: 
  • Humanetics Corporation (Humanetics) presented data related to its new drug candidate, BIO 300, at the 68th Annual International Radiation Research Society Meeting, October 16-19, 2022.
  • Data presented included the protective effects of BIO 300 Oral Powder for both acute hematological and long-term pulmonary effects of acute radiation exposure when administered prophylactically.
  • Data were also presented on the recently completed phase 1 clinical study of BIO 300 Oral Powder in healthy volunteers ( NCT04650555 ).
  • The research presented was supported by grants from the US Department of Defenses Congressionally Directed Medical Research Program.

Reefer Container for Pharmaceutical Sector Global Market to Grow at 12.5% Annually Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022
HVAC, Pharmaceutical, Health, Manufacturing, Adoption, Assistant, Government, Transport, Growth, Royal commission, Strategic National Stockpile, Vaccine, Policy, CAGR, HHS, Personal protective equipment, Hapag-Lloyd, SNS, Bureau of Economic Analysis, Temperature, Pharmaceutical marketing, PPE, Economics, United States Department of Health and Human Services, Bureau, Office of the Assistant Secretary for Preparedness and Response, Fesco Transport Group, COVID-19, European Commission, Cardinal Health, Pharmaceutical industry

The "Reefer Container for Pharmaceutical Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application Type and Container Size" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Reefer Container for Pharmaceutical Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application Type and Container Size" report has been added to ResearchAndMarkets.com's offering.
  • The reefer container for pharmaceutical market is expected to reach US$ 6,391.8 million by 2028 from US$ 2,846.7 million in 2021.
  • The growth of the reefer container for pharmaceutical market in North America is primarily attributed to the increasing demand for refrigerated medicines, vaccines, and blood plasma along with the government policies encouraging international trade.
  • The growing initiatives from the European Commission for designing regulations and policies drive the growth of the reefer container for the pharmaceutical market in Europe.

CED Report: To Better Prepare for the Next Public Health Crisis, Government and Business Will Need Closer Collaboration

Retrieved on: 
Tuesday, May 24, 2022
Diabetes, The Conference Board, Public health, Infection, Biosurveillance, Strategic National Stockpile, Review, FEMA, COVID-19, Mortality, Conference, Smoking, Pandemic, Economic development, Solution, DHS, Government, Alaska Natives, Committee for Economic Development, HHS, Policy, Recruit, Research, Student, Hospital, Department, Death, North Carolina National Guard, Vaccine, Health, Learning, IV, American Indians, Private, FDA, Federation, Congress, Therapy, COVID, Committee, Public policy, National Guard, Hard, Ageing, USAID, Public sector, Leadership, Patient, CED, PPE, Obesity, Private sector, Workforce, Congressional Budget Office, Health education, School, Hypertension, Pharmaceutical industry, Animal, Design, Health insurance, Tutoring, Risk management, Medicine, Management, AIAN

The overriding theme of the study is the importance of close public-private collaboration at all levels for dealing with public health crises.

Key Points: 
  • The overriding theme of the study is the importance of close public-private collaboration at all levels for dealing with public health crises.
  • "Hard experience has taught us how inextricably linked the public and private sectors are during a national health emergency.
  • Cost-responsible consumer choice among competing private health care plans will drive the system toward quality, affordable health care for all.
  • Business should embrace its role as a trusted source of information for employees during a public health crisis.

AirBoss Announces Record First Quarter 2022 Results

Retrieved on: 
Wednesday, May 11, 2022
BOS, Internet, HHS, Assistant, Health, Income, Strategic National Stockpile, Company, History, EBITDA, International, Depreciation, Original equipment manufacturer, EDT, Microsoft Teams, ASPR, AirBoss of America, Investment, Personal protective equipment, Mission statement, Public expenditure, PPE, Solution, Meeting, The Meeting, Natural rubber, Shareholder, Engineering, COVID-19, Color, Rubber industry in Malaysia, TSX, Workforce, Plastech Engineered Products, Weather, TTM, SUV, ADG, Board, Safety, Technology, NIOSH, IFRS, Microsoft, International Financial Reporting Standards, Acquisition, Growth, OTCQX, Medical device, Renewable energy, Retail, Fine chemical, Risk management

The Board of Directors of the Company has approved a quarterly dividend of C$0.10 per common share, to be paid on July 15, 2022 to shareholders of record at June 30, 2022.

Key Points: 
  • The Board of Directors of the Company has approved a quarterly dividend of C$0.10 per common share, to be paid on July 15, 2022 to shareholders of record at June 30, 2022.
  • In the AirBoss Defense Group segment, net sales increased by 41.9%, to $63,962 in Q1 2022, compared to Q1 2021.
  • Gross profit at AirBoss Defense Group for Q1 2022 increased by 32.7% to $27,671, from $20,846 in Q1 2021.
  • At Engineered Products, net sales for Q1 2022 decreased by 7.8%, to $29,840, compared with Q1 2022.

SilverCrest's Las Chispas Construction Update - Commissioning on Schedule for Q2, 2022

Retrieved on: 
Thursday, April 28, 2022
Well, ORP, Vein, Legislation, CEO, Power, Mining, Time, Powerline, Feasibility study, LOM, Omicron, Creston Electric Instruments, KV, Task force, Qualified person (European Union), COVID-19, Forward-looking statement, Risk, Silvercrest, Company, LTIFR, Rehabilitation, SMP, CFE, Multimedia, Strategic National Stockpile, Line of credit, Technical report, News, View, National instrument, CPG, Map, Climate change, Maintenance, Rail transport, Renewable energy, Uranium, Construction, Potash, BC, H1, Q3, Ausenco, Project

The construction of this section is now complete and was energized (2.0 MW) in early Q2, 2022.

Key Points: 
  • The construction of this section is now complete and was energized (2.0 MW) in early Q2, 2022.
  • The H1, 2022 exploration focus at Las Chispas is to map and sample unexplored areas and generate new drill targets.
  • SilverCrest currently has one (1) drill rig operating at Las Chispas where the focus remains on completion of construction and process plant commissioning.
  • These include, without limitation, statements with respect to: the strategic plans, timing and expectations for the Company's construction and exploration programs at the Las Chispas Project and the start-up of processing at the Las Chispas Mine in Q2, 2022.

Scorpion Biological Services Announces New Kansas Commercial Biomanufacturing Facility

Retrieved on: 
Tuesday, April 26, 2022
Texas A&M University, BRI, Drug development, Manhattan Area Technical College, Department of Defence, Cell biology, National Bio and Agro-Defense Facility, Research, CDMO, Strategic National Stockpile, Kansas State University, Department, SNS, Biomedical Advanced Research and Development Authority, Engineering, Workforce, LinkedIn, Anthrax, Virology, Development, RTG, NBAF, Public health, BARDA, Partnership, Defense, Bioreactor, Precision medicine, Wilson State Park (Kansas), Fine chemical, Pharmaceutical industry, Scorpion

MANHATTAN, Kan., April 26, 2022 /PRNewswire/ -- Biopharmaceutical contract development and manufacturing organization (CDMO) Scorpion Biological Services (Scorpion) today announced a planned development partnership with a private developer, the State of Kansas, and local and university affiliates, which will support the construction of a new biodefense-focused large molecule and biologics biomanufacturing facility in Manhattan, Kansas.

Key Points: 
  • MANHATTAN, Kan., April 26, 2022 /PRNewswire/ -- Biopharmaceutical contract development and manufacturing organization (CDMO) Scorpion Biological Services (Scorpion) today announced a planned development partnership with a private developer, the State of Kansas, and local and university affiliates, which will support the construction of a new biodefense-focused large molecule and biologics biomanufacturing facility in Manhattan, Kansas.
  • The design and engineering of the facility is being led by CRB Group, a nationally recognized firm focused on designing and building biomanufacturing facilities.
  • Upon completion, Scorpion projects that the facility will have a billion-dollar impact on the State of Kansas, and employ over 500 individuals, largely from the local Kansas talent pool.
  • Scorpion Biological Services is working to expand the reach of precision medicine to more people within multiple therapeutic areas.